No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
If you’re involved in licensing technology from a university, research institution, or federal lab—or granting those rights to others—managing royalties is one of the most critical (and complex) parts of the process. In this blog post, you’ll learn exactly how royalties work in technology transfer agreements, what responsibilities fall on both licensors and licensees, and how to stay compliant while minimizing administrative headaches. In short, you need a clear understanding of the agreement terms, airtight recordkeeping, and the right tools to stay organized.
Organizations managing technology transfer agreements find that MetaComet’s automation tools eliminate the administrative headaches while maintaining compliance and accurate recordkeeping.

The primary purpose of a “technology transfer agreement” (or TTA) is to facilitate the legal and practical transfer of intellectual property (IP) from one entity to another. The term most commonly refers to a legal contract that outlines the terms under which one party (often a research institution, university, or company) grants another party (or licensee) the right to use, develop, or commercialize a specific technology.
Specific purposes of the agreement include:
Technology transfer agreements are an umbrella term covering several related contract types, including license, employment, material transfer, CRADA, and non-disclosure agreements, that together govern how IP moves from a research institution to a commercial licensee. Various types of agreements enter into the tech transfer process.
For a closer look at how licensing models like exclusive licensing, non-exclusive licensing, and CRADAs play out specifically in biotech deals, see our guide to biotech technology transfer.
A technology transfer agreement’s core components typically include the grant of rights, IP ownership terms, financial terms, confidentiality provisions, warranties, indemnification, and termination conditions, each governing a different part of how the licensor and licensee’s relationship works over the life of the deal.
Multiple agreement types, diverse IP licensing, complex revenue distributions, various stakeholders – why struggle with these complexities when our automation tools handle everything? Save 90% of your revenue distribution management workload. Find out how: talk to our team of royalty experts today.
The licensed materials in a technology transfer agreement are often, but not necessarily, scientific or technological inventions. They may or may not be copyrightable material, patents, or trademarks. The two things they all have in common is that they are newly created and have some sort of commercial value.
Some types of IP that are often licensed in tech transfer agreements include:
The licensor, typically a university or research institution’s technology transfer office, receives the revenue from a technology transfer agreements’ fees and royalties, then distributes portions to the parties who enabled the research, per its own institutional and legal policies. Common recipients include inventors, faculty, research programs, labs, and departments. For a fuller look at how a technology transfer office evaluates and licenses research in the first place, see our technology transfer industry overview.
Technology transfer agreements typically move through six stages: invention disclosure, evaluation, negotiation, execution, commercialization, and monitoring, with the financial and royalty obligations covered elsewhere on this page concentrated in the final stage.

Royalties play a central role in many technology transfer agreements as a way for the licensee to compensate the licensor. The licensee will make periodic payments to the licensor based on a percentage of sales, a fixed amount per unit sold, or usage rates. Royalty-related clauses in a TTA will typically include:
A technology transfer office (TTO) needs a strong grasp of the financial and administrative aspects of royalty management to effectively manage royalties and distributions arising from technology transfer agreements, while ensuring compliance with institutional policies, legal requirements, and stakeholder expectations. Specifically, the TTO must:
To learn how a TTO collects statements, calculates shares, and pays recipients, see our overview of technology transfer office software and process.
The licensee needs a clear record and understanding of the agreement terms, just as the licensor receiving the royalty payments does. In particular, they need to know:
A missed royalty payment typically triggers a cure period defined in the agreement, giving the licensee a set window, often 30 to 60 days, to pay before the licensor can pursue interest charges, penalties, or termination. Most agreements also specify whether interest accrues automatically on late payments or only after formal notice.
Royalty disputes are typically resolved through the audit process defined in the agreement, where the licensor reviews the licensee’s sales and payment records against the contract terms before escalating to negotiation, mediation, or arbitration. Most TTAs specify a dispute resolution path, and many require informal negotiation before either party can pursue formal arbitration or litigation.
A licensor can terminate or convert a technology transfer agreement if the licensee fails to meet its diligence obligations, which are the commercialization milestones the licensee agreed to pursue. Since minimum royalties and diligence terms are closely linked, a pattern of missed minimums is often the first signal a licensor uses to evaluate whether diligence obligations are being met.
Whether you’re a TTO or a licensee, MetaComet® can automate the calculation, payment, and tracking of all your payments related to technology transfer agreements.
Whichever side of the tech transfer agreement you’re on, MetaComet can save you time, minimize risks, and eliminate the stress around technology transfer payments. Contact us to discuss your needs and find out how MetaComet can work for you.

David Marlin is the President and Co-Founder of MetaComet® Systems, a prominent provider of royalty automation tools. Since founding the company in 2000, David has spearheaded the development of a suite of best-in-class systems that effectively facilitate royalty processes for nearly 200 publishers. David has also served as the chair for The Book Industry Study Group’s Rights Committee and Digital Sales Committee.
Before establishing MetaComet Systems, David served as a technology consultant for renowned publishers, collaborating with notable companies such as Random House, Penguin, HarperCollins, Holtzbrinck, Macmillan, Scholastic, Time Warner, and many others. David holds both an MBA and a BA from Columbia University in New York.
"*" indicates required fields